Clinical Trials With
TheraSphere® YTTRIUM-90 GLASS MICROSPHERES

Did You Know:
Liver Cancer is the fifth-most-common cancer in men and the ninth-most-common cancer in women.10

EPOCH

Protocol TS-102 / NCT01483027
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) in patients with metastatic colorectal carcinoma of the liver who have failed first-line chemotherapy

STOP-HCC

Protocol TS-103 / NCT01556490
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) in the treatment of patients with unresectable hepatocellular carcinoma (HCC)

YES-P

Protocol TS-104 / NCT01887717
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) versus the standard of care (sorafenib) for the treatment of advanced HCC with portal vein thrombosis

CAUTION - Investigational Device.
Limited by United States law to investigational use.

TheraSphere® is manufactured for Biocompatibles UK Ltd, a BTG International group company. TheraSphere is a trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. TheraSphere is a registered trademark in the US, EU and certain other territories. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in the US, EU and certain other territories.
All rights reserved.
US-TMR-2015-1111.